Tag Archives: LDL

November, 2018

14 November
Amgen Presents Results Highlighting the Long-Term Safety and Efficacy of Repatha in the Longest Duration Study of a PCSK9 Inhibitor to Date

THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutralizing antibodies. …
Share

10 February
Appeals Court Grants Stay of Permanent Injunction for Praluent During Appeals Process

Paris, France and Tarrytown, New York – February 8, 2017 – Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) and Sanofi announced today that the United States Court of Appeals for the Federal Circuit has stayed (suspended) the permanent injunction for Praluent® (alirocumab) Injection pending the companies’ appeal. This ruling (available here) means …
Share

1 November
Pfizer Discontinues Development of its Investigational PCSK9 Inhibitor

Tuesday, November 1, 2016 – 6:30am EDT — Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for …
Share

31 July
FDA Approves Sanofi’s PCSK9 Drug Praluent

PARIS and TARRYTOWN, N.Y., July 24, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as …
Share